Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases

Recruiting

Phase 2

RAD101Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases

Sponsor:

Radiopharm Theranostics, Ltd

Code:

NCT06777433

Conditions

Brain Metastases From Solid Tumors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

RAD101 (18F-FPIA)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-18. This information was provided to ClinicalTrials.gov by Radiopharm Theranostics, Ltd on 2025-09-19.